Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2025-04-02 Annual Report
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Document d'Enregistrement Universel
Annual Report Classification · 100% confidence The document is titled 'document d’enregistrement universel' and was filed with the AMF (French financial market authority) under EU regulation 2017/1129. It includes detailed company information, business description, strategic partnerships, clinical development updates, risk factors, and a letter from the Chairman. It also states it contains the company's financial statements for the fiscal year ended December 31, 2024, prepared under French accounting standards and IFRS. The document is comprehensive and covers the full fiscal year, indicating it is an official annual report. The length (15,000 characters) and content confirm it is not a mere announcement or certification but a full report. Therefore, this document corresponds to an Annual Report (10-K equivalent). FY 2024
2025-04-02 French
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024
Report Publication Announcement Classification · 95% confidence The document is a press release from Nanobiotix announcing its 2024 financial results and the filing of its Universal Registration Document (DEU) and Form 20-F. While it contains financial highlights and summaries, it explicitly states that the full annual reports (DEU and 20-F) are available on their website and the respective regulatory portals. According to the 'Menu vs Meal' rule, this document serves as an announcement of the publication of the annual reports rather than the annual report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2024
2025-04-02 French
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
Earnings Release Classification · 100% confidence The document is a press release from Nanobiotix announcing its full-year 2024 financial results. It provides a summary of operational highlights, financial performance (revenue, R&D expenses, net loss, cash position), and explicitly states that the full annual reports (URD and 20-F) have been filed and are available on their website. Because this document is a summary announcement of financial results rather than the full annual report itself, and it includes key financial highlights, it is classified as an Earnings Release. FY 2024
2025-04-02 English
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces the date when the company will report its financial results for the fourth quarter and full year 2024 (April 2, 2025), followed by a conference call and webcast (April 3, 2025). This is a forward-looking announcement about the release of financial results, not the results document itself (which would be an ER or 10-K). Since the document's primary function is to announce the publication of financial results and the associated call details, it fits the definition of a Report Publication Announcement (RPA). It is not a Call Transcript (CT) because it is the announcement, not the transcript of the call itself.
2025-03-31 English
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
Report Publication Announcement Classification · 98% confidence The document is a press release titled "NANOBIOTIX PUBLIERA SES RÉSULTATS FINANCIERS ET OPÉRATIONNELS DE L'EXERCICE 2024 LE 2 AVRIL 2025" (NANOBIOTIX WILL PUBLISH ITS ANNUAL FINANCIAL AND OPERATIONAL RESULTS FOR FISCAL YEAR 2024 ON APRIL 2, 2025). It explicitly announces the future date for the release of annual results and schedules a conference call. This structure—announcing *when* a report will be released, rather than containing the full report itself—fits the definition of a Report Publication Announcement (RPA). The document length (4595 chars) is also consistent with a brief announcement rather than a full Annual Report (10-K) or Interim Report (IR).
2025-03-31 French
Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC loc
Earnings Release Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces preliminary data from a Phase 1 clinical study evaluating NBTXR3 (JNJ-1900) for NSCLC patients. It details clinical findings (safety profile, PFS, OS) and mentions that the data will be presented at a conference (European Lung Cancer Congress 2025). This format—a formal announcement of scientific/clinical progress, often released before a full regulatory filing or earnings report—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses specifically on clinical trial results and is presented as a press release, it aligns best with the 'Earnings Release' category, which often includes key operational and clinical milestones for biotech/pharma companies, even if no specific financial period results are the primary focus. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a specific regulatory filing like DIRS or DIV. Given the content is a major announcement of study data, ER is the most appropriate fit among the provided options, as it serves as the primary communication vehicle for such news. Q1 2025
2025-03-27 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.